Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patterns’ based approach

Rus, Tomaž; Tomše, Petra; Jensterle, Luka; Grmek, Marko; Pirtošek, Zvezdan; Eidelberg, David; Tang, Chris C.; Trošt, Maja

doi:10.1007/s00259-020-04785-z

Cited by 29 publications

(29 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSP was predicted with 94% specificity and a 94% positive predictive value 50 . When a movement disorder specialist is not readily available, the application of such metabolic patterns improves the diagnostic accuracy by 10 to 15% for PD and 20% for atypical parkinsonism 51 . Compared to functional MRI (fMRI), metabolic 18 F‐FDG PET patterns performed at the group level may provide specific advantages.…”

Section: Advances In Image Analysesmentioning

confidence: 99%

“… 50 When a movement disorder specialist is not readily available, the application of such metabolic patterns improves the diagnostic accuracy by 10 to 15% for PD and 20% for atypical parkinsonism. 51 Compared to functional MRI (fMRI), metabolic 18 F‐FDG PET patterns performed at the group level may provide specific advantages. The cerebral metabolic rate of glucose measured by 18 F‐FDG PET is known to precede the relative transient decrease in blood oxygen level–dependent signals without any magnetic limitations.…”

Section: Advances In Image Analysesmentioning

confidence: 99%

See 1 more Smart Citation

Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast‐Developing Field

Verger

Grimaldi

Ribeiro

et al. 2021

Annals of Neurology

View full text Add to dashboard Cite

The early differential diagnosis of Parkinson disease and atypical parkinsonism is a major challenge. The use of single photon emission computed tomography (SPECT)/positron emission tomography (PET) molecular imaging to investigate parkinsonism is a fast-developing field. Imaging biomarker research may potentially lead to more accurate disease detection, enabling earlier diagnosis and treatment. This review summarizes recent SPECT/PET advances in radiopharmaceuticals and imaging technologies/analyses that improve the diagnosis of neurodegenerative parkinsonism. We are currently witnessing a turning point in the field. Integrating molecular imaging as a diagnostic technique represents an opportunity to reassess the strategies for diagnosing neurodegenerative parkinsonism.

show abstract

Section: Advances In Image Analysesmentioning

confidence: 99%

Section: Advances In Image Analysesmentioning

confidence: 99%

Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast‐Developing Field

Verger

Grimaldi

Ribeiro

et al. 2021

Annals of Neurology

View full text Add to dashboard Cite

show abstract

“…We measured PDRP assortativity, degree centrality, clustering coe cient, characteristic path length, and small-worldness in FDG PET scans previously taken from 96 PD patients and 22 healthy control (HC) subjects (Table S1A) 15 . We evaluated the same metrics in FDG PET scans from an independent group of 146 PD and 39 HC subjects (Table S1B) studied under similar conditions 16,17 .…”

Section: Network Assortativity Is Higher In Pd Than In Healthy Controlsmentioning

confidence: 99%

Adaptive and pathological connectivity responses in Parkinson’s disease brain networks

Schindlbeck

Nguyen

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Functional imaging has been used extensively to identify and validate disease-specific networks as biomarkers in neurodegenerative disorders. It is not known, however, if connectivity patterns in these networks differ with disease progression compared to the beneficial adaptations that may also occur over time. To distinguish the two responses, we focused on assortativity, the tendency for network connections to link nodes with similar properties. High assortativity is associated with unstable, inefficient flow through the network. Low assortativity, by contrast, involves more diverse connections that are also more robust and efficient. We found that in Parkinson’s disease (PD), network assortativity increased with over time. Assoratitivty was high in clinically aggressive genetic variants, but low for genes associated with slow progression. Dopaminergic treatment increased assortativity despite improving motor symptoms, but subthalamic gene therapy, which remodels PD networks, reduced this measure compared to sham surgery. Assortativity may therefore be useful in evaluating disease-modifying therapies.

show abstract

“…Eidelberg and colleagues have used FDG PET brain imaging combined with an automated image classification algorithm to classify parkinsonian patients as PD or APS at the time when the clinical diagnosis was still uncertain [ 141 ]. Two cohorts were considered—one clinically diagnosed by movement disorder specialists following consensus criteria 2 years after imaging—which was the standard of truth—and one diagnosed by general neurologists not necessarily following consensus criteria 2 years after imaging.…”

Section: Utility Of Fdg Pet For Discriminating Between Atypical Parkinsonian Syndromesmentioning

confidence: 99%

Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism

Brooks

2021

Neurotherapeutics

View full text Add to dashboard Cite

In this paper, the structural and functional imaging changes associated with sporadic and genetic Parkinson’s disease and atypical Parkinsonian variants are reviewed. The role of imaging for supporting diagnosis and detecting subclinical disease is discussed, and the potential use and drawbacks of using imaging biomarkers for monitoring disease progression is debated. Imaging changes associated with nonmotor complications of PD are presented. The similarities and differences in imaging findings in Lewy body dementia, Parkinson’s disease dementia, and Alzheimer’s disease are discussed.

show abstract

Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patterns’ based approach

Cited by 29 publications

References 35 publications

Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast‐Developing Field

Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast‐Developing Field

Adaptive and pathological connectivity responses in Parkinson’s disease brain networks

Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism

Contact Info

Product

Resources

About